PART I [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Unaudited Q1 FY2021 financial statements show increased assets and net income, with reduced operating cash flow due to working capital needs [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheets detail the company's financial position, showing an increase in total assets and liabilities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2020 | June 30, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $27,366 | $30,478 | | Inventories, net | $35,165 | $27,972 | | Total current assets | $86,410 | $79,024 | | Total assets | $128,556 | $120,203 | | **Liabilities & Equity** | | | | Accounts payable | $17,769 | $12,509 | | Lines of credit – current | $10,000 | $10,000 | | Total current liabilities | $37,133 | $27,806 | | Total liabilities | $57,425 | $48,828 | | Total stockholders' equity | $71,131 | $71,375 | | Total liabilities and stockholders' equity | $128,556 | $120,203 | [Condensed Consolidated Statements of Income and Comprehensive Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income%20and%20Comprehensive%20Income) The income statements reflect a significant increase in net sales and net income for the quarter Condensed Consolidated Statement of Income (in thousands, except per share data) | Metric | Q1 FY2021 (ended Sep 30, 2020) | Q1 FY2020 (ended Sep 30, 2019) | | :--- | :--- | :--- | | Net sales | $39,726 | $29,195 | | Gross profit | $6,005 | $4,384 | | Income (loss) from operations | $2,085 | $(55) | | Net income | $2,258 | $96 | | Basic EPS | $0.35 | $0.01 | | Diluted EPS | $0.35 | $0.01 | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Stockholders' equity slightly decreased due to stock repurchases and unrealized losses, despite net income - Total stockholders' equity slightly decreased from **$71.4 million** at June 30, 2020, to **$71.1 million** at September 30, 2020, primarily due to a **$1.7 million** repurchase of common stock and a **$1.1 million** unrealized loss on derivative instruments, which offset the **$2.3 million** in net income for the period[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash flows show a significant decrease in operating cash, leading to an overall net decrease in cash Condensed Consolidated Statement of Cash Flows (in thousands) | Cash Flow Activity | Three Months Ended Sep 30, 2020 | Three Months Ended Sep 30, 2019 | | :--- | :--- | :--- | | Net cash provided by operating activities | $110 | $4,593 | | Net cash used in investing activities | $(1,479) | $(1,118) | | Net cash used in financing activities | $(1,743) | $(15) | | Net (decrease) increase in cash | $(3,112) | $3,460 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Key notes detail revenue streams, customer concentration, tax rates, and stock repurchase activities - Beta-alanine (CarnoSyn®) related raw material sales and royalty/licensing income was **$2.7 million** for the quarter, down from **$3.2 million** in the prior-year period[33](index=33&type=chunk) - The company has significant customer concentration, with one customer accounting for **60%** of net sales (**$24.0 million**) in the quarter ended Sep 30, 2020, up from **49%** in the prior year period[64](index=64&type=chunk)[104](index=104&type=chunk) Net Sales by Business Segment (in thousands) | Segment | Q1 FY2021 (ended Sep 30, 2020) | Q1 FY2020 (ended Sep 30, 2019) | | :--- | :--- | :--- | | Private-label contract manufacturing | $37,047 | $26,009 | | Patent and trademark licensing | $2,679 | $3,186 | | **Total Net Sales** | **$39,726** | **$29,195** | - The company's effective tax rate was **(28.0)%** for the quarter, primarily due to a discrete tax benefit related to the CARES Act and new Treasury regulations regarding GILTI[77](index=77&type=chunk)[79](index=79&type=chunk)[80](index=80&type=chunk) - On September 18, 2020, the Board authorized a **$2.0 million** increase to the stock repurchase plan, bringing the total authorization to **$12.0 million**, and during the quarter, the company repurchased **235,390 shares** for **$1.7 million**[85](index=85&type=chunk)[86](index=86&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 FY2021 sales growth, segment performance, and provides a positive fiscal 2021 outlook - The COVID-19 pandemic has positively impacted sales, particularly for immune and wellness products, and as a precautionary measure, the company withdrew **$10 million** from its credit facility to ensure liquidity[101](index=101&type=chunk)[102](index=102&type=chunk)[104](index=104&type=chunk) Results of Operations Summary (in thousands) | Metric | Q1 FY2021 | Q1 FY2020 | % Change | | :--- | :--- | :--- | :--- | | Total net sales | $39,726 | $29,195 | 36% | | Gross profit | $6,005 | $4,384 | 37% | | SG&A expenses | $3,920 | $4,439 | (12)% | | Income (loss) from operations | $2,085 | $(55) | 3,891% | | Net income | $2,258 | $96 | 2,252% | - Private-label contract manufacturing sales increased **42%** due to higher sales to the largest customer, including a new product, and sales to other new and existing customers[103](index=103&type=chunk)[115](index=115&type=chunk) - Patent and trademark licensing (CarnoSyn® beta-alanine) sales decreased **16%** due to some customers switching to generic beta-alanine and the negative impact of COVID-19 on the sports nutrition industry[105](index=105&type=chunk)[116](index=116&type=chunk) - The company expects annualized fiscal 2021 net sales to increase between **30% to 50%** compared to fiscal 2020, with an anticipated operating income of **5% to 7%** of net sales[109](index=109&type=chunk) - Net cash from operating activities was only **$0.1 million**, a significant decrease from **$4.6 million** in the prior-year period, primarily due to a **$7.2 million** increase in inventory to support anticipated sales[121](index=121&type=chunk)[123](index=123&type=chunk) [Item 4. Controls and Procedures](index=30&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective with no material changes to internal controls during the quarter - Based on an evaluation as of September 30, 2020, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective[132](index=132&type=chunk) - There were no changes in internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, these controls[133](index=133&type=chunk) PART II [Item 1. Legal Proceedings](index=31&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no material pending legal proceedings as of November 10, 2020 - The company is not a party to any material pending legal proceedings as of November 10, 2020[137](index=137&type=chunk) [Item 1A. Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) Investors are directed to review risk factors detailed in the company's 2020 Annual Report on Form 10-K - Investors are advised to review the risk factors detailed in the company's 2020 Annual Report on Form 10-K[138](index=138&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=31&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered equity sales and detailed common stock repurchases during the quarter Common Stock Repurchases (Q1 FY2021) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | July 2020 | 7,931 | $6.94 | | August 2020 | 216,492 | $7.37 | | September 2020 | 10,967 | $8.07 | | **Total** | **235,390** | **N/A** | - As of September 30, 2020, approximately **$1.96 million** remained available for future repurchases under the company's stock repurchase program[140](index=140&type=chunk) [Item 3. Defaults Upon Senior Securities](index=31&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported for the period - None[141](index=141&type=chunk) [Item 5. Other Information](index=31&type=section&id=Item%205.%20Other%20Information) No other material information was reported for the period - None[142](index=142&type=chunk)[143](index=143&type=chunk) [Item 6. Exhibits](index=33&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the report, including CEO/CFO certifications and XBRL data files - Exhibits filed with this report include CEO and CFO certifications (Rule 13a-14(a)/15d-14(a) and Section 1350) and XBRL Interactive Data Files[145](index=145&type=chunk)

Table of Contents Delaware 84-1007839 (State of incorporation) (IRS Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2020 (Commission file number) NATURAL ALTERNATIVES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 000-15701 1535 Faraday Ave Carlsbad, CA 92008 (760) 744-7700 (Address of principal exec ...

[Forward-Looking Statements](index=3&type=section&id=SPECIAL%20NOTE%20ABOUT%20FORWARD-LOOKING%20STATEMENTS) The report contains forward-looking statements regarding future events and financial performance, subject to various risks and uncertainties - Forward-looking statements address future financial results, patent licensing, new product acceptance, and operational efficiency, subject to risks and uncertainties including COVID-19 impact[8](index=8&type=chunk)[9](index=9&type=chunk) [PART I FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Unaudited condensed consolidated financial statements show a decrease in stockholders' equity and a net loss for Q3 FY2020, driven by lower sales and uncollectible accounts [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets increased to **$118.4 million** due to lease assets and cash, while total liabilities rose to **$47.6 million** from lease liabilities and credit draw, decreasing equity to **$70.7 million** Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2020 | June 30, 2019 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $33,315 | $25,040 | | Total current assets | $76,988 | $71,386 | | Operating lease right-of-use assets | $18,881 | $— | | **Total assets** | **$118,355** | **$93,490** | | **Liabilities & Equity** | | | | Line of credit – current | $10,000 | $— | | Total current liabilities | $25,805 | $14,250 | | Long-term liability – operating leases | $19,230 | $— | | **Total liabilities** | **$47,606** | **$17,406** | | **Total stockholders' equity** | **$70,749** | **$76,084** | [Condensed Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20%28Loss%29%20Income%20and%20Comprehensive%20%28Loss%29%20Income) The company reported a **net loss of $4.0 million** for Q3 2020, a significant decline from prior year's net income, driven by **28% lower net sales** and a **$3.3 million provision for uncollectible accounts** Key Income Statement Data (in thousands, except per share data) | Metric | Q3 2020 | Q3 2019 | Nine Months 2020 | Nine Months 2019 | | :--- | :--- | :--- | :--- | :--- | | Net sales | $25,482 | $35,455 | $83,780 | $108,030 | | Gross profit | $2,894 | $6,327 | $12,339 | $19,926 | | (Loss) income from operations | $(4,223) | $1,835 | $(3,580) | $6,766 | | Net (loss) income | $(4,015) | $1,994 | $(3,443) | $6,734 | | Diluted EPS | $(0.61) | $0.27 | $(0.51) | $0.95 | - The quarterly loss was significantly impacted by a **$3.28 million provision for uncollectible accounts receivable**[12](index=12&type=chunk) [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Total stockholders' equity decreased to **$70.7 million** due to a **$3.4 million net loss** and **$3.5 million in common stock repurchases** - The company repurchased **423,676 shares** of common stock for **$3.5 million** during the nine months ended March 31, 2020[17](index=17&type=chunk) - A **net loss of $3.4 million** for the nine-month period directly reduced retained earnings[17](index=17&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operations was **$5.2 million**, while financing activities provided **$6.5 million** from a **$10.0 million credit draw**, leading to an **$8.3 million increase in cash** to **$33.3 million** Cash Flow Summary (Nine Months Ended March 31, in thousands) | Cash Flow Activity | 2020 | 2019 | | :--- | :--- | :--- | | Net cash provided by operating activities | $5,164 | $7,580 | | Net cash used in investing activities | $(3,407) | $(2,630) | | Net cash provided by (used in) financing activities | $6,518 | $(903) | | **Net increase in cash and cash equivalents** | **$8,275** | **$4,047** | | **Cash and cash equivalents at end of period** | **$33,315** | **$27,660** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail accounting policies, including ASC 842 adoption, revenue recognition, segment performance, customer dependency, debt, and COVID-19 impact, notably a **$3.3 million reserve** for a terminated customer's receivables - Adoption of ASC 842 (Leases) resulted in **$20.7 million** in right-of-use assets and **$20.9 million** in lease liabilities on the balance sheet[48](index=48&type=chunk)[49](index=49&type=chunk) - A **$3.3 million reserve** for accounts receivable and **$1.0 million** for inventory was established due to the termination of the Kaged Muscle customer relationship[43](index=43&type=chunk)[66](index=66&type=chunk) - The company drew **$10 million** from its credit facility as a precautionary liquidity measure due to COVID-19 uncertainty[62](index=62&type=chunk) - **Two major customers** represented **65.5%** of gross accounts receivable as of March 31, 2020[65](index=65&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes a **22% net sales decrease** to a **38% decline** in sales to its largest customer and a **24% drop** in licensing revenue, alongside a **$4.3 million reserve** for a terminated customer and a **$10 million credit draw** due to COVID-19 [Executive Overview and Business Strategy](index=26&type=section&id=Executive%20Overview%20and%20Business%20Strategy) The company focuses on private-label contract manufacturing and CarnoSyn® beta-alanine patent licensing, with a strategy to diversify customers, commercialize patents, and improve operational efficiencies - The primary business involves **private-label contract manufacturing** for the nutritional supplement industry[100](index=100&type=chunk) - Key revenue streams include raw material sales and **licensing of CarnoSyn® and SR CarnoSyn® beta-alanine trademarks and patents**[100](index=100&type=chunk) - Strategic focus includes **diversifying the sales base**, expanding **beta-alanine patent commercialization**, and **improving operational efficiencies**[101](index=101&type=chunk)[116](index=116&type=chunk) [Impact of COVID-19 on Our Business](index=26&type=section&id=Impact%20of%20COVID-19%20on%20Our%20Business) The COVID-19 pandemic creates significant uncertainty, with potential impacts on supply chains, employee availability, and customer demand, leading to a **$10 million credit facility withdrawal** - Facilities in the US and Europe continue to operate as **essential and critical manufacturers**[102](index=102&type=chunk) - Potential risks include **limitations on suppliers, employees, carriers, and customer operations**[105](index=105&type=chunk) - The company withdrew **$10 million** from its credit facility as a precautionary liquidity measure due to the pandemic[103](index=103&type=chunk) [Results of Operations](index=28&type=section&id=Results%20of%20Operations) Q3 2020 saw **total net sales fall 28% to $25.5 million**, resulting in a **54% gross profit decline** and a **$4.2 million operating loss**, driven by sales drops and a **$3.3 million bad debt expense** Results of Operations Summary (Three Months Ended March 31, in thousands) | Metric | 2020 | 2019 | % Change | | :--- | :--- | :--- | :--- | | Total net sales | $25,482 | $35,455 | (28)% | | Gross profit | $2,894 | $6,327 | (54)% | | Gross profit % | 11.4% | 17.8% | - | | SG&A expenses | $7,117 | $4,492 | 58% | | (Loss) income from operations | $(4,223) | $1,835 | (330)% | | Net (loss) income | $(4,015) | $1,994 | (301)% | - SG&A expenses increased primarily due to a **$3.3 million bad debt expense** for a former customer's receivable[121](index=121&type=chunk) - The contract manufacturing gross profit margin declined due to a **$4.3 million total reserve** for a former customer's receivables and inventory[126](index=126&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) Primary liquidity sources are cash from operations and a credit facility, with **$33.3 million in cash** and **$5.2 million from operations**, supplemented by a **$10.0 million credit draw** for COVID-19 precautions - Cash and cash equivalents totaled **$33.3 million** as of March 31, 2020[132](index=132&type=chunk) - Net cash provided by operating activities was **$5.2 million** for the nine months ended March 31, 2020, a decrease from the prior year[124](index=124&type=chunk) - A **$10.0 million balance** was outstanding on the loan facility as of March 31, 2020, drawn as a precautionary measure[130](index=130&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Natural Alternatives International, Inc. is exempt from providing this disclosure - The company is not required to provide Item 3 disclosure due to its qualification as a **smaller reporting company**[135](index=135&type=chunk) [Item 4. Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2020, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that disclosure controls and procedures were **effective** as of March 31, 2020[137](index=137&type=chunk) - No material changes to internal control over financial reporting occurred during the quarter[138](index=138&type=chunk) [PART II OTHER INFORMATION](index=33&type=section&id=PART%20II%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in ordinary course legal proceedings, with no material pending cases as of May 14, 2020, and no expected material adverse effects - The company engages in various claims and legal proceedings in the ordinary course of business[140](index=140&type=chunk) - As of May 14, 2020, no material pending legal proceedings involved the company or its subsidiary NAIE[141](index=141&type=chunk) [Item 1A. Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors) The COVID-19 pandemic is a significant risk factor, causing supply chain disruptions and creating uncertainty regarding its full impact on operational and financial performance - The **COVID-19 pandemic** is a significant risk factor, impacting global economic conditions and potentially affecting company operations and business[143](index=143&type=chunk) - The duration and financial impact of pandemic-related disruptions remain **uncertain** and cannot be reasonably estimated[143](index=143&type=chunk)[144](index=144&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=33&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company did not sell unregistered equity securities but repurchased **210,832 shares** of common stock for **$1.8 million** during Q3 2020 under its repurchase plan Purchases of Equity Securities (Q3 2020) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | Jan 2020 | 180,238 | $8.80 | | Feb 2020 | — | — | | Mar 2020 | 30,594 | $6.47 | | **Total** | **210,832** | **-** | [Item 3. Defaults Upon Senior Securities](index=35&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) There were no defaults upon senior securities during the reporting period - No defaults upon senior securities were reported[148](index=148&type=chunk) [Item 4. Mine Safety Disclosures](index=35&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - This item is **not applicable** to the company[149](index=149&type=chunk) [Item 5. Other Information](index=35&type=section&id=Item%205.%20Other%20Information) No other information is required to be reported under this item - No other information is reported for this item[150](index=150&type=chunk) [Item 6. Exhibits](index=35&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including CEO and CFO certifications and XBRL data files - The report includes **certifications from the CEO and CFO** as required by Rule 13a-14(a)/15d-14(a)[152](index=152&type=chunk) - **XBRL Instance Documents** and related taxonomy files are filed with this report[152](index=152&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2019 000-15701 (Commission file number) NATURAL ALTERNATIVES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 84-1007839 (State of incorporation) (IRS Employer Identification No.) 1535 Faraday Ave Carlsbad, CA 92008 (760) 736-7700 (Address of pr ...

000-15701 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 (Commission file number) NATURAL ALTERNATIVES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 84-1007839 (State of incorporation) (IRS Employer Identification No.) 1535 Faraday Ave Carlsbad, CA 92008 (760) 736-7700 (Address of p ...

Table of Contents FORM 10-K ANNUAL REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2019 000-15701 (Commission file number) NATURAL ALTERNATIVES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 84-1007839 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State of incorporation) (IRS Employer Identification No.) 1535 Faraday Ave Carlsbad, CA 92008 (760) 744-7700 (Address of principal exec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 000-15701 (Commission file number) NATURAL ALTERNATIVES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 84-1007839 (State of incorporation) (IRS Employer Identification No.) 1535 Faraday Ave Carlsbad, CA 92008 (760) 736-7700 (Address of princ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2018 000-15701 (Commission file number) NATURAL ALTERNATIVES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 84-1007839 (State of incorporation) (IRS Employer Identification No.) 1535 Faraday Ave Carlsbad, CA 92008 (760) 736-7700 (Address of pr ...